Breaking News Instant updates and real-time market news.

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13

Stoke Therapeutics presents preclinical data from studies of STK-001

Stoke Therapeutics announced preclinical data from studies of STK-001 "that showed significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome." New data from electroencephalography recordings showed 76% of DS mice treated with STK-001 were seizure free compared to 48% that were treated with a placebo, the company said in a statement. An 80% reduction in the average number of spontaneous seizures was also observed among treated DS mice compared to placebo. These data were presented in a poster session at the American Epilepsy Society Annual Meeting in Baltimore. "The data on STK-001 from this mouse model give us confidence in our approach to treating the underlying cause of Dravet syndrome by restoring Nav1.1 protein expression to near normal levels," said Edward Kaye, Chief Executive Officer of Stoke Therapeutics. "The reductions in mortality previously observed with STK-001 were compelling and the new EEG data provide further evidence of the potential for STK-001 to impact Dravet syndrome by reducing seizure frequency and possibly preventing seizures entirely. What is particularly remarkable is that these data were generated from a spontaneous seizure model, which we believe accurately reflects the clinical situation in people with Dravet syndrome."

STOK Stoke Therapeutics
$28.91

3.99 (16.01%)

07/15/19
FBCO
07/15/19
INITIATION
Target $35
FBCO
Outperform
Stoke Therapeutics initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster started coverage of Stoke Therapeutics with an Outperform rating and $35 price target. Noting that Stoke's lead asset, STK-001, is in development for Dravet syndrome, the analyst argues that the drug's intuitive mechanism of action and its demonstrated "strong" improvement in survival in a Dravet mouse model supports optimism for the program. Auster expects initial clinical results in 2021 and thinks that, despite the early stage nature of the story, a rapid and meaningful de-risking of the clinical program based on proof-of-concept data from a small number of patients is possible, based on early clinical results, which may lead to significant share appreciation.
10/25/19
HCWC
10/25/19
INITIATION
Target $30
HCWC
Buy
Stoke Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay initiated coverage of Stoke Therapeutics with a Buy rating and $30 price target. The analyst believes TANGO, an antisense oligonucleotide platform, is an "intriguing approach" at combating haploinsufficiencies.
11/12/19
BTIG
11/12/19
INITIATION
Target $46
BTIG
Buy
Stoke Therapeutics initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated coverage of Stoke Therapeutics with a Buy rating and $46 price target. The analyst cites the potential of the company's technology built by the inventors of SPINRAZA, along with the large informatics engine designed to identify additional disease states that might be treated via modification of pre-mRNA splicing. The "systematic screening methodology called TANGO" has nearly "boundless potential" toward treating a large number of genetic diseases and likely many chronic diseases, Shrader writes in his research note.
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arlo Technologies (ARLO) resumed with a Buy at Deutsche Bank. 2. Clarivate Analytics (CCC) initiated with a Hold at Stifel. 3. Stoke Therapeutics (STOK) initiated with a Buy at BTIG. 4. BioMarin (BMRN), Biogen (BIIB), and Amgen (AMGN) were initiated with a Buy at SunTrust. 5. Corteva (CTVA) initiated with a Buy at Redburn. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

10:40
01/17/20
01/17
10:40
01/17/20
10:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ES

Eversource

$87.74

0.01 (0.01%)

, CMS

CMS Energy

$65.28

-0.1 (-0.15%)

10:32
01/17/20
01/17
10:32
01/17/20
10:32
Downgrade
Eversource, CMS Energy, NextEra Energy rating change  »

NextEra, CMS Energy,…

ES

Eversource

$87.74

0.01 (0.01%)

CMS

CMS Energy

$65.28

-0.1 (-0.15%)

NEE

NextEra Energy

$251.86

-0.41 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

TWTR

Twitter

$34.14

-0.05 (-0.15%)

, SNAP

Snap

$19.15

0.9 (4.93%)

10:31
01/17/20
01/17
10:31
01/17/20
10:31
On The Fly
Analysts bullish on Pinterest, Snap as Twitter gets downgraded to Neutral »

Shares of social media…

TWTR

Twitter

$34.14

-0.05 (-0.15%)

SNAP

Snap

$19.15

0.9 (4.93%)

PINS

Pinterest

$23.30

0.34 (1.48%)

FB

Facebook

$221.31

-0.47 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Options
Busy week for 50 Cent as another massive block of calls is bought »

Busy week for 50 Cent as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

, KKR

KKR

$31.17

0.67 (2.20%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Periodicals
KKR not discussing going hostile on Dave & Buster's, Axios reports »

KKR (KKR) has a…

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

KKR

KKR

$31.17

0.67 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 31

    Jan

  • 26

    Feb

VWAGY

Volkswagen

$0.00

(0.00%)

10:28
01/17/20
01/17
10:28
01/17/20
10:28
Periodicals
VW set to acquire 20% stake in Chinese battery maker Guoxuan, Reuters reports »

Volkswagen is poised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast »

Tech Strategist…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
UBS services analysts to hold an analyst/industry conference call »

Services Analyst Lasser,…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Wolfe Research industrials analysts to hold an analyst/industry webcast »

Multi-Idndustry Analyst…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

10:25
01/17/20
01/17
10:25
01/17/20
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

MIDD

Middleby

$111.11

1.51 (1.38%)

, MCD

McDonald's

$212.00

1.14 (0.54%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Recommendations
Middleby, McDonald's, Welbilt analyst commentary  »

Middleby equimpment may…

MIDD

Middleby

$111.11

1.51 (1.38%)

MCD

McDonald's

$212.00

1.14 (0.54%)

WBT

Welbilt

$15.39

-0.06 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CMS

CMS Energy

$65.31

-0.07 (-0.11%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
CMS Energy rating change  »

CMS Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

ES

Eversource

$87.64

-0.09 (-0.10%)

10:24
01/17/20
01/17
10:24
01/17/20
10:24
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NEE

NextEra Energy

$252.14

-0.13 (-0.05%)

10:23
01/17/20
01/17
10:23
01/17/20
10:23
Downgrade
NextEra Energy rating change  »

NextEra Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

STT

State Street

$85.19

4.185 (5.17%)

10:22
01/17/20
01/17
10:22
01/17/20
10:22
Hot Stocks
State Street management 'confident in capital position' »

Comment from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Conference/Events
Wolfe Research energy analysts to hold an analyst/industry luncheon »

Energy Analysts…

GLD

SPDR Gold Shares

$146.63

0.33 (0.23%)

10:20
01/17/20
01/17
10:20
01/17/20
10:20
Options
Gold ETF call volume surges on March spread »

Gold ETF call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOLS

Evolus

$11.43

0.25 (2.24%)

10:19
01/17/20
01/17
10:19
01/17/20
10:19
Recommendations
Evolus analyst commentary  »

Evolus shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEL

Velocity Financial

$0.00

(0.00%)

10:18
01/17/20
01/17
10:18
01/17/20
10:18
Syndicate
Breaking Syndicate news story on Velocity Financial »

Velocity Financial opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
01/17/20
01/17
10:17
01/17/20
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
01/17/20
01/17
10:16
01/17/20
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
FX Action: The dollar »

FX Action: The dollar was…

10:15
01/17/20
01/17
10:15
01/17/20
10:15
General news
U.S. JOLTS reported job openings dropped -561k to 6,800k in November »

U.S. JOLTS reported job…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.